Related Experiment Videos
A simple quantitative bradykinesia test in MPTP-treated mice.
Research Communications in Chemical Pathology and Pharmacology
|December 1, 1985
Summary
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinsonism in mice, causing dopamine depletion in the striatum. This MPTP mouse model is valuable for screening anti-Parkinsonian drugs like L-DOPA.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that induces Parkinson's-like pathology in animal models.
- Idiopathic Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra.
Purpose of the Study:
- To establish and validate the MPTP-treated mouse as a suitable experimental model for Parkinson's disease research.
- To assess the utility of a pole test for evaluating bradykinesia and screening anti-Parkinsonian agents.
Main Methods:
- Mice were injected with MPTP (300 mg/kg total dose) to induce neurotoxicity.
- Dopamine and norepinephrine concentrations in the striatum were measured biochemically.
- A pole test was employed to evaluate bradykinesia in MPTP-treated mice.
- The efficacy of L-DOPA in alleviating bradykinesia was assessed dose-dependently.
Main Results:
- MPTP administration significantly decreased striatal dopamine levels by 75% and norepinephrine by 50%.
- These neurochemical changes mimicked those observed in human Parkinson's disease patients.
- MPTP-treated mice exhibited dose-dependent alleviation of bradykinesia upon L-DOPA administration.
Conclusions:
- MPTP-treated mice serve as a valuable preclinical model for studying Parkinsonism.
- The pole test is an effective tool for screening potential anti-Parkinsonian drugs in this model.